The Major Molecular Causes of Familial Hypercholesterolemia

被引:3
作者
Phuong Kim Truong [1 ]
Thuan Duc Lao [1 ]
Thuy Ai Huyen Le [1 ]
机构
[1] Ho Chi Minh City Open Univ, Fac Biotechnol, Dept Pharmaceut & Med Biotechnol, Ho Chi Minh City, Vietnam
关键词
Apolipoprotein B-100 (ApoB-100); Familial Hypercholesterolemia; Low Density Lipoprotein Receptor; Low Density Lipoprotein Receptor Adapter Protein; Proprotein Convertase Subtilisin/Kexin Type 9;
D O I
10.18311/ajprhc/2018/20031
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Familial Hypercholesterolemia (FH) is a common dominant disorder of cholesterol metabolism characterized by elevated serum cholesterol level which results in increasing risk of many diseases. The major cause of FH is the loss-of-function in Low Density Lipoprotein Receptor (LDLR), Apolipoprotein B-100 (ApoB-100), Low Density Lipoprotein Receptor Adapter Protein (LDLRAP1), and Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) gene that revealed to the defects in the uptake and degradation of Low Density Lipoprotein (LDL) via the LDLR pathway. In this review, we have highlighted the molecular disorder in LDLR, ApoB-100, LDLRAP1 and PCSK gene, leading to the possible accession on early diagnosis, screening of FH based on the clinical characteristics, family history, evaluated LDL-Cholesterol levels and recently genetic testing aided, hence molecular based therapy will be applied or recommended to FH patients.
引用
收藏
页码:60 / 68
页数:9
相关论文
共 47 条
  • [1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    [J]. NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [2] The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations
    Agarwala, Anandita
    Jones, Peter
    Nambi, Vijay
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2015, 17 (01) : 1 - 8
  • [3] Novel Mutations Identification in Exon 4 of LDLR Gene in Patients With Moderate Hypercholesterolemia in a Venezuelan Population
    Arraiz, Nailet
    Bermudez, Valmore
    Rondon, Netxibeth
    Reyes, Francia
    Borjas, Lisbeth
    Solis, Ernesto
    Mujica, Endrina
    Prieto, Carem
    Reyna, Nadia
    Velasco, Manuel
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2010, 17 (03) : 325 - 329
  • [4] The assembly of apoB-containing lipoproteins: A structural biology point of view
    Banaszak, Leonard J.
    Ranatunga, Wasantha K.
    [J]. ANNALS OF MEDICINE, 2008, 40 (04) : 253 - 267
  • [5] The molecular mechanism for the genetic disorder familial defective apolipoprotein B100
    Borén, J
    Ekström, U
    Ågren, B
    Nilsson-Ehle, P
    Innerarity, TL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (12) : 9214 - 9218
  • [6] FAMILIAL HYPERCHOLESTEROLEMIA - DEFECTIVE BINDING OF LIPOPROTEINS TO CULTURED FIBROBLASTS ASSOCIATED WITH IMPAIRED REGULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE-ACTIVITY
    BROWN, MS
    GOLDSTEIN, JL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1974, 71 (03) : 788 - 792
  • [7] PCSK9: Regulation and Target for Drug Development for Dyslipidemia
    Burke, Amy C.
    Dron, Jacqueline S.
    Hegele, Robert A.
    Huff, Murray W.
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 57, 2017, 57 : 223 - 244
  • [8] Chaudhary R, 2017, WORLD J CARDIOL, V9, P76, DOI 10.4330/wjc.v9.i2.76
  • [9] Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia
    Davis, Kyle A.
    Miyares, Marta A.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (12) : 1001 - 1008
  • [10] GENETIC-EVIDENCE THAT THE PUTATIVE RECEPTOR-BINDING DOMAIN OF APOLIPOPROTEIN-B (RESIDUE-3130 TO RESIDUE-3630) IS NOT THE ONLY REGION OF THE PROTEIN INVOLVED IN INTERACTION WITH THE LOW-DENSITY-LIPOPROTEIN RECEPTOR
    DUNNING, AM
    HOULSTON, R
    FROSTEGARD, J
    REVILL, J
    NILSSON, J
    HAMSTEN, A
    TALMUD, P
    HUMPHRIES, S
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1096 (03) : 231 - 237